R230C and C230C Variants of ABCA1 and Glyburide Response

Phase 4 Completed 85 enrolled National Institute of Medical Sciences and Nutrition Salvador Zubiran

Non-randomizedParallel-groupSingle-blindBasic science

Summary

The objective of the study is to know if the R230C and C230C variants of the ATP-binding cassette transporter A1 (ABCA1) gene are associated with a smaller glucose lowering effect compared to the wild type allele (R230R) in patients with type 2 diabetes.

Timeline

Start: 2011-03
Primary completion: 2012-11
Completion: 2012-12

Outcome

Met primary endpoint

paper However, the dose of sulfonylurea was significantly higher in the R230C participants compared with the R230R subjects (3.3±2.1 vs 6.3±5 mg/day, p<0.001). PMID 23273975 ↗

Publications

Aguilar-Salinas CA, Munoz-Hernandez LL, Cobos-Bonilla M, Ramirez-Marquez MR, Ordonez-Sanchez ML, Mehta R, Medina-Santillan R, Tusie-Luna MT. The R230C variant of the ATP binding cassette protein A1 (ABCA1) gene is associated with a decreased response to glyburide therapy in patients with type 2 diabetes mellitus. Metabolism. 2013 May;62(5):638-41. doi: 10.1016/j.metabol.2012.11.006. Epub 2012 Dec 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glyburide	Small molecule	2.5 mg	Oral
Subject	Glyburide	Small molecule	5 mg	Oral
Subject	Glyburide	Small molecule	7.5 mg	Oral
Subject	Glyburide	Small molecule	10 mg	Oral